Myriad Genetics (MYGN) PT Raised to $22 at Piper Jaffray

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. SAP
7. CSX
8. LRCX
9. KNX
10. ELV

Go back to Myriad Genetics (MYGN) PT Raised to $22 at Piper Jaffray

Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results

February 7, 2017 4:06 PM EST

Second-Quarter 2017 Total Revenues of $196.5 MillionSecond-Quarter 2017 GAAP Diluted EPS of $0.09 and Adjusted EPS of $0.26Company Updates Fiscal Year 2017 Guidance and Issues Fiscal Third-Quarter 2017 Guidance

SALT LAKE CITY, Feb. 07, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and personalized medicine, today announced financial results for its fiscal second-quarter 2017, provided an update on recent business highlights, updated its fiscal year 2017 financial guidance and issued fiscal third-quarter 2017 financial guidance.

"Revenues this quarter reached their... More